G1 Therapeutics Provides Second Quarter 2022 Financial Results and Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Nasdaq, S&P 500 futures rise ahead of key jobs report
- Oil rallies for the week as U.S.-Iran fighting resumes; diesel hits record high
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- Fed’s Waller open to September rate hold - if disinflation holds up
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
G1 Therapeutics, Inc. (GTHX) Tops Q2 EPS by 10c
August 3, 2022 6:44 AM EDTG1 Therapeutics, Inc. (NASDAQ: GTHX) reported Q2 EPS of ($0.92), $0.10 better than the analyst estimate of ($1.02). Revenue for the quarter came in at $10.57 million versus the consensus estimate of $9.09 million.
For earnings history and earnings-related data on G1 Therapeutics, Inc. (GTHX) click here.
... More